373 related articles for article (PubMed ID: 20932174)
1. Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor-chemotherapy combinations as an anticancer strategy for solid tumors.
Johnson N; Shapiro GI
Expert Opin Ther Targets; 2010 Nov; 14(11):1199-212. PubMed ID: 20932174
[TBL] [Abstract][Full Text] [Related]
2. Novel small molecule cyclin-dependent kinases modulators in human clinical trials.
Senderowicz AM
Cancer Biol Ther; 2003; 2(4 Suppl 1):S84-95. PubMed ID: 14508085
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
Santo L; Siu KT; Raje N
Semin Oncol; 2015 Dec; 42(6):788-800. PubMed ID: 26615126
[TBL] [Abstract][Full Text] [Related]
4. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
Senderowicz AM
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S61-73. PubMed ID: 12819936
[TBL] [Abstract][Full Text] [Related]
5. Small Molecule CDK Inhibitors for the Therapeutic Management of Cancer.
Goel B; Tripathi N; Bhardwaj N; Jain SK
Curr Top Med Chem; 2020; 20(17):1535-1563. PubMed ID: 32416692
[TBL] [Abstract][Full Text] [Related]
6. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy.
Grant S; Roberts JD
Drug Resist Updat; 2003 Feb; 6(1):15-26. PubMed ID: 12654284
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-dependent kinases in DNA damage response.
Kciuk M; Gielecińska A; Mujwar S; Mojzych M; Kontek R
Biochim Biophys Acta Rev Cancer; 2022 May; 1877(3):188716. PubMed ID: 35271993
[TBL] [Abstract][Full Text] [Related]
8. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
Nandi S; Dey R; Dey S; Samadder A; Saxena AK
Anticancer Agents Med Chem; 2022; 22(3):485-498. PubMed ID: 34503422
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors (CDKIs) and the DNA damage response: The link between signaling pathways and cancer.
Amani J; Gorjizadeh N; Younesi S; Najafi M; Ashrafi AM; Irian S; Gorjizadeh N; Azizian K
DNA Repair (Amst); 2021 Jun; 102():103103. PubMed ID: 33812232
[TBL] [Abstract][Full Text] [Related]
10. Targeting the cell cycle: a new approach to cancer therapy.
Schwartz GK; Shah MA
J Clin Oncol; 2005 Dec; 23(36):9408-21. PubMed ID: 16361640
[TBL] [Abstract][Full Text] [Related]
11. Cyclin-dependent kinase inhibitors as anticancer drugs.
Krystof V; Uldrijan S
Curr Drug Targets; 2010 Mar; 11(3):291-302. PubMed ID: 20210754
[TBL] [Abstract][Full Text] [Related]
12. Less-well known functions of cyclin/CDK complexes.
Palmer N; Kaldis P
Semin Cell Dev Biol; 2020 Nov; 107():54-62. PubMed ID: 32386818
[TBL] [Abstract][Full Text] [Related]
13. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
Roskoski R
Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the DNA damage response by cyclin-dependent kinases.
Trovesi C; Manfrini N; Falcettoni M; Longhese MP
J Mol Biol; 2013 Nov; 425(23):4756-66. PubMed ID: 23603016
[TBL] [Abstract][Full Text] [Related]
15. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
Di Giovanni C; Novellino E; Chilin A; Lavecchia A; Marzaro G
Expert Opin Investig Drugs; 2016 Oct; 25(10):1215-30. PubMed ID: 27606939
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase pathways as targets for cancer treatment.
Shapiro GI
J Clin Oncol; 2006 Apr; 24(11):1770-83. PubMed ID: 16603719
[TBL] [Abstract][Full Text] [Related]
17. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
Elbæk CR; Petrosius V; Sørensen CS
Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Galons H; Oumata N; Meijer L
Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
[TBL] [Abstract][Full Text] [Related]
19. Behind the wheel and under the hood: functions of cyclin-dependent kinases in response to DNA damage.
Wohlbold L; Fisher RP
DNA Repair (Amst); 2009 Sep; 8(9):1018-24. PubMed ID: 19464967
[TBL] [Abstract][Full Text] [Related]
20. New Insights into CDK Regulators: Novel Opportunities for Cancer Therapy.
Bury M; Le Calvé B; Ferbeyre G; Blank V; Lessard F
Trends Cell Biol; 2021 May; 31(5):331-344. PubMed ID: 33676803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
